poisar

Stock

Sarepta Therapeutics, Inc. Common Stock (DE) SRPT

$15.54+0.68%

Overview

SRPT market data

Price History

SRPT price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
24.89
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$7.13
Diluted earnings per share over the trailing twelve months.
Beta
0.22
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$14.68 – $25.32
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.6K · P/B 1.98 · P/S 0.74.

Company News

9 captured
8-K filing — Sarepta Therapeutics, Inc. (SRPT)SEC EDGAR · Jul 27, 2026, 1:08 PM
Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug IngramBenzinga · Jul 27, 2026, 12:37 PM
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20Benzinga · Jul 9, 2026, 3:40 PM
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price TargetBenzinga · Jul 9, 2026, 12:15 PM
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy DrugsBenzinga · Jun 30, 2026, 4:50 PM
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027Benzinga · Jun 30, 2026, 12:40 PM
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market TodayBenzinga · Jun 17, 2026, 5:40 PM
My Top 3 Biotech Stocks for May 2026The Motley Fool · May 20, 2026, 4:15 PM
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT InvestmentGlobenewswire Inc · May 18, 2026, 7:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock